- Home
- LYB vs HOLX Comparison
LYB vs HOLX Comparison
Compare LYB & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYB | HOLX |
|---|---|---|
| Founded | 1955 | 1985 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Electronics |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 16.9B |
| IPO Year | 2010 | 1995 |
Fundamental Metrics
Financial Performance| Metric | LYB | HOLX |
|---|---|---|
| Price | $73.17 | $76.02 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 16 | 13 |
| Target Price | $68.88 | ★ $77.89 |
| AVG Volume (30 Days) | 7.2M | ★ 9.3M |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | ★ $30,153,000,000.00 | $4,100,500,000.00 |
| Revenue This Year | $1.93 | $4.74 |
| Revenue Next Year | $0.13 | $5.03 |
| P/E Ratio | ★ N/A | $96.23 |
| Revenue Growth | N/A | ★ 1.74 |
| 52 Week Low | $41.58 | $51.90 |
| 52 Week High | $83.94 | $76.07 |
Technical Indicators
Market Signals| Indicator | LYB | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 50.84 | 69.09 |
| Support Level | $70.22 | $75.10 |
| Resistance Level | $83.94 | N/A |
| Average True Range (ATR) | 3.53 | 0.19 |
| MACD | -1.29 | 0.03 |
| Stochastic Oscillator | 31.53 | 95.19 |
Price Performance
Historical ComparisonAbout LYB LyondellBasell Industries NV (Netherlands)
LyondellBasell is a petrochemical producer with operations in the United States, Europe, and Asia. The company is the world's largest producer of polypropylene and also a major producer of polyethylene and propylene oxide. Its chemicals are used in various consumer and industrial end products. Well over half of LyondellBasell's production comes from its North American operations.
About HOLX Hologic Inc.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.